{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:04:34Z","timestamp":1792598674239,"version":"4.5.0"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sarcoma, a rare and highly heterogeneous malignant neoplasm originating from mesenchymal tissues, is broadly classified into bone sarcoma and soft tissue sarcoma depending on where they occur. Patients with advanced or metastatic sarcomas face a poor prognosis. Conventional chemotherapy regimens demonstrate limited efficacy with substantial adverse effects, and therapeutic options remain scarce for those experiencing chemotherapy failure or intolerance. The development of tyrosine kinase inhibitors has brought the treatment of sarcoma into a new stage. As a multi-target tyrosine kinase inhibitor, anlotinib exerts antitumor effects through dual mechanisms of anti-angiogenesis and direct tumor cell proliferation inhibition. While it has been increasingly reported to treat bone and soft tissue sarcoma with promising efficacy, there has been no systematic analysis of this application.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed, Embase, the Cochrane Library, Web of Science, Vip (China), Cnki (China), WanFang (China), and SinoMed (China) databases were systematically searched for relevant studies, published from the inception of each database to July 12, 2025, without language restrictions. The primary outcomes included the objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and adverse events (AEs). These data were extracted and analyzed using STATA 17.0 software.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 16 studies with 787 participants were included in this meta-analysis. In terms of clinical efficacy, the pooled outcomes indicated that ORR and DCR were 8.8% (95%CI: 6.2%\u201311.7%) and 70.7% (95%CI: 64.8%\u201376.2%), respectively. Median PFS ranged from 2.7 to 12.4 months, with a pooled result of 6.68 months (95%CI: 5.37\u20137.98). Median OS ranged from 11.4 to 42 months, with a mean of 19 \u00b1 9.5 months. Furthermore, the 3-, 6-, and 9-month PFS rates were 71.1%, 48.4%, and 32.0%, respectively. The 6- and 12-month OS rates were 85.7% and 67.8%, respectively. With regard to clinical safety, the three most common all-grade treatment-related adverse events associated with anlotinib were hand-foot syndrome (34.7%), hypertension (32.4%), and pharyngalgia (30.6%). However, the incidence of grade 3\u20134 adverse events was relatively low and manageable; for example, hypertension (7.9%), hand-foot syndrome (2.9%), and pneumothorax (3.0%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Based on the evidence provided by this meta-analysis, anlotinib demonstrates promising clinical efficacy and a favorable safety profile in patients with advanced bone and soft tissue sarcomas, although additional high-quality clinical studies are required to further evaluate its properties and toxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420251103981<\/jats:ext-link>\n                      , PROSPERO.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1703261","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T05:14:58Z","timestamp":1764306898000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and safety of anlotinib for the treatment of advanced bone and soft tissue sarcomas: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"15","author":[{"given":"Zhipeng","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiwen","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengjun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1186\/2045-3329-2-14","article-title":"The epidemiology of sarcoma","volume":"2","author":"Burningham","year":"2012","journal-title":"Clin sarcoma Res"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/his.14265","article-title":"Updates from the 2020 world health organization classification of soft tissue and bone tumours","volume":"78","author":"Anderson","year":"2021","journal-title":"Histopathology"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq276","article-title":"Osteosarcoma","volume":"21","author":"Ritter","year":"2010","journal-title":"Ann Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13045-024-01580-3","article-title":"New strategies in soft tissue sarcoma treatment","volume":"17","author":"Spalato-Ceruso","year":"2024","journal-title":"J Hematol Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(14)70063-4","article-title":"Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial","volume":"15","author":"Judson","year":"2014","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.04.034","article-title":"Immune checkpoint inhibitors in treatment of soft-tissue sarcoma: A systematic review and meta-analysis","volume":"152","author":"Saerens","year":"2021","journal-title":"Eur J Cancer (Oxford England: 1990)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"6330","DOI":"10.1038\/s41598-021-83877-8","article-title":"Cardioprotective effects of exercise training on doxorubicin-induced cardiomyopathy: a systematic review with meta-analysis of preclinical studies","volume":"11","author":"Ghignatti","year":"2021","journal-title":"Sci Rep"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2002.37263","article-title":"Role of angiogenesis in tumor growth and metastasis","volume":"29","author":"Folkman","year":"2002","journal-title":"Semin Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1200\/jco.2017.74.9812","article-title":"Pathologic angiogenesis of Malignant vascular sarcomas: implications for treatment","volume":"36","author":"Khan","year":"2018","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-0255","article-title":"Differential expression of VEGFA isoforms regulates metastasis and response to anti-VEGFA therapy in sarcoma","volume":"77","author":"English","year":"2017","journal-title":"Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1042\/bj20101603","article-title":"Fibroblast growth factors and their receptors in cancer","volume":"437","author":"Wesche","year":"2011","journal-title":"Biochem J"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-12-1646","article-title":"Distinct effects of ligand-induced PDGFR\u03b1 and PDGFR\u03b2 signaling in the human rhabdomyosarcoma tumor cell and stroma cell compartments","volume":"73","author":"Ehnman","year":"2013","journal-title":"Cancer Res"},{"key":"B13","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13045-018-0664-7","article-title":"Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development","volume":"11","author":"Shen","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"11503","DOI":"10.1200\/JCO.2018.36.15_suppl.11503","article-title":"Anlotinib for metastasis\u00a0soft tissue sarcoma: A randomized, double-blind, placebo-controlled and\u00a0multi-centered clinical trial","volume":"36","author":"Chi","year":"2018","journal-title":"J Clin Oncol."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3039","article-title":"Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 phase 3 randomized clinical trial","volume":"4","author":"Han","year":"2018","journal-title":"JAMA Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-20-2950","article-title":"Anlotinib in locally advanced or metastatic medullary thyroid carcinoma: A randomized, double-blind phase IIB trial","volume":"27","author":"Li","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (minors): development and validation of a new instrument","volume":"73","author":"Slim","year":"2003","journal-title":"ANZ J surg"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.11124\/jbisrir-d-19-00099","article-title":"Methodological quality of case series studies: an introduction to the JBI critical appraisal tool","volume":"18","author":"Munn","year":"2020","journal-title":"JBI evidence synthesis"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1186\/2049-3258-72-39","article-title":"Metaprop: a Stata command to perform meta-analysis of binomial data","volume":"72","author":"Nyaga","year":"2014","journal-title":"Arch Public Health = Arch belges sante publique"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-3766","article-title":"Safety and efficacy of anlotinib, a multikinase angiogenesis inhibitor, in patients with refractory metastatic soft-tissue sarcoma","volume":"24","author":"Chi","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-3983","article-title":"First-line anlotinib treatment for soft-tissue sarcoma in chemotherapy-ineligible patients: an open-label, single- arm, phase 2 clinical trial","volume":"30","author":"Li","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1000-8179.2018.20.632","article-title":"Anlotinib hydrochloride capsules for advanced soft tissue sarcoma: Single-center data analysis of a stage II multicenter clinical trial","volume":"45","author":"Liu","year":"2018","journal-title":"Chin J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"102240","DOI":"10.1016\/j.eclinm.2023.102240","article-title":"Anlotinib as a maintenance treatment for advanced soft tissue sarcoma after first-line chemotherapy (ALTER-S006): a multicentre, open-label, single-arm, phase 2 trial","volume":"64","author":"Xu","year":"2023","journal-title":"eClinicalMedicine"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.811687","article-title":"Anlotinib for recurrent or metastatic primary Malignant bone tumor: A multicenter, single-arm trial","volume":"12","author":"Tang","year":"2022","journal-title":"Front Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"103258","DOI":"10.1016\/j.eclinm.2025.103258","article-title":"Safety and feasibility of anlotinib in children with high risk, recurrent or refractory sarcomas: an open-label, single-centre, single-arm, phase Ia\/Ib trial","volume":"84","author":"Lu","year":"2025","journal-title":"eClinicalMedicine"},{"key":"B26","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s00432-023-05575-4","article-title":"Efficacies of anlotinib monotherapy versus gemcitabine-based chemotherapy for patients with advanced soft tissue sarcoma after the failure of anthracycline-based chemotherapy","volume":"150","author":"Zheng","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4286","article-title":"Efficacy and safety of anlotinib in patients with unresectable or metastatic bone sarcoma: A retrospective multiple institution study","volume":"10","author":"Liu","year":"2021","journal-title":"Cancer Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3781\/j.issn.1000-7431.2023.2302-0085","article-title":"Safety and efficacy of anlotinib in patients with unresectable or metastatic bone and soft-tissue sarcomas: a retrospective institution study","volume":"43","author":"Pang","year":"2023","journal-title":"Tumor"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112152-20210820-00632","article-title":"Efficacy and safety of Anlotinib in the treatment of advanced sarcoma","volume":"45","author":"Qiang","year":"2023","journal-title":"Chin J Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-020-01015-z","article-title":"Switch maintenance therapy with anlotinib after chemotherapy in unresectable or metastatic soft tissue sarcoma: a single-center retrospective study","volume":"39","author":"Liu","year":"2021","journal-title":"Investigational New Drugs"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1097\/cad.0000000000001023","article-title":"Efficacy and safety of anlotinib in patients with unresectable or metastatic well-differentiated\/dedifferentiated liposarcoma: a single-center retrospective study","volume":"32","author":"Li","year":"2021","journal-title":"Anti-Cancer Drugs"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1097\/cad.0000000000001154","article-title":"Anlotinib treatment in elderly patients with unresectable or metastatic soft tissue sarcoma: a retrospective study","volume":"33","author":"Zhang","year":"2022","journal-title":"Anti-Cancer Drugs"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.13916","article-title":"Retrospective review of safety and efficacy of anlotinib in advanced osteosarcoma with metastases after failure of standard multimodal therapy","volume":"19","author":"Li","year":"2023","journal-title":"Asia Pac J Clin Oncol"},{"key":"B34","author":"Gan","year":"2022"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-020-00912-7","article-title":"Retrospective review of the activity\u00a0and safety of apatinib and anlotinib in patients with advanced osteosarcoma and soft tissue sarcoma","volume":"38","author":"Tian","year":"2020","journal-title":"Invest New Drugs"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100250","article-title":"Phase I\/II study of single-agent lenvatinib in children and adolescents with refractory or relapsed solid Malignancies and young adults with osteosarcoma (ITCC-050)(\u2606)","volume":"6","author":"Gaspar","year":"2021","journal-title":"ESMO Open"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3892\/or.2017.5735","article-title":"Anti-angiogenesis target therapy for advanced osteosarcoma (Review)","volume":"38","author":"Xie","year":"2017","journal-title":"Oncol Rep"},{"key":"B38","doi-asserted-by":"publisher","first-page":"368","DOI":"10.3978\/j.issn.2305-5839.2015.12.33","article-title":"Biological characterization of soft tissue sarcomas","volume":"3","author":"Hayashi","year":"2015","journal-title":"Ann Transl Med"},{"key":"B39","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1302\/2058-5241.5.200069","article-title":"Treatment options in unresectable soft tissue and bone sarcoma of the extremities and pelvis - a systematic literature review","volume":"5","author":"Smolle","year":"2020","journal-title":"EFORT Open Rev"},{"key":"B40","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13045-016-0332-8","article-title":"Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors","volume":"9","author":"Sun","year":"2016","journal-title":"J Hematol Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1080\/15384101.2021.1949132","article-title":"Apatinib inhibits cell proliferation and migration of osteosarcoma via activating LINC00261\/miR-620\/PTEN axis","volume":"20","author":"Han","year":"2021","journal-title":"Cell Cycle (Georgetown Tex)"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-020-01644-7","article-title":"The efficacy and safety of Apatinib mesylate in the treatment of metastatic osteosarcoma patients who progressed after standard therapy and the VEGFR2 gene polymorphism analysis","volume":"25","author":"Liu","year":"2020","journal-title":"Int J Clin Oncol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"109587","DOI":"10.1016\/j.biopha.2019.109587","article-title":"Efficacy and safety of the VEGFR2 inhibitor Apatinib for metastatic soft tissue sarcoma: Chinese cohort data from NCT03121846","volume":"122","author":"Liu","year":"2019","journal-title":"Biomed Pharmacother."},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.662318","article-title":"Assessment of efficiency and safety of apatinib in advanced bone and soft tissue sarcomas: A systematic review and meta-analysis","volume":"11","author":"Long","year":"2021","journal-title":"Front Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-23-0257","article-title":"Regorafenib plus vincristine and irinotecan in pediatric patients with recurrent\/refractory solid tumors: an innovative therapy for children with cancer study","volume":"29","author":"Casanova","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25864","article-title":"Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity","volume":"129","author":"Wilhelm","year":"2011","journal-title":"Int J Cancer"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(16)30507-1","article-title":"Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"17","author":"Mir","year":"2016","journal-title":"Lancet Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(18)30742-3","article-title":"Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study","volume":"20","author":"Duffaud","year":"2019","journal-title":"Lancet Oncol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1186\/s12885-025-13722-y","article-title":"Efficacy and safety of regorafenib in the treatment of bone sarcomas: systematic review and meta-analysis","volume":"25","author":"Han","year":"2025","journal-title":"BMC Cancer"},{"key":"B50","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41392-019-0049-6","article-title":"Pazopanib in advanced soft tissue sarcomas","volume":"4","author":"Lee","year":"2019","journal-title":"Signal transduction targeted Ther"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-01167-2","article-title":"Efficacy and safety of approved first-line tyrosine kinase inhibitor treatments in metastatic renal cell carcinoma: A network meta-analysis","volume":"37","author":"Manz","year":"2020","journal-title":"Adv Ther"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-023-04766-3","article-title":"Real-world outcomes of pazopanib in metastatic soft tissue sarcoma: a retrospective Turkish oncology group (TOG) study","volume":"149","author":"Bilici","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3390\/medsci7030048","article-title":"Real-world experiences with pazopanib in patients with advanced soft tissue and bone sarcoma in northern California","volume":"7","author":"Seto","year":"2019","journal-title":"Med Sci (Basel Switzerland)"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0242982","article-title":"Anlotinib for refractory advanced non-small-cell lung cancer: A systematic review and meta-analysis","volume":"15","author":"Yu","year":"2020","journal-title":"PLoS One"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1345203","article-title":"Tyrosine kinase inhibitors in patients with advanced anaplastic thyroid cancer: an effective analysis based on real-world retrospective studies","volume":"15","author":"Kuang","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1393404","article-title":"Efficacy and safety of a novel TKI (anlotinib) for the treatment of advanced digestive system neoplasms: a systematic review and meta-analysis","volume":"15","author":"Zhou","year":"2024","journal-title":"Front Immunol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1703261\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T05:15:02Z","timestamp":1764306902000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1703261\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":56,"alternative-id":["10.3389\/fonc.2025.1703261"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1703261","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"article-number":"1703261"}}